CHAPTER 7: B Cell-based Therapies for Multiple Sclerosis

Michael Osherov, Ron Milo

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

1 Scopus citations

Abstract

The traditional view of multiple sclerosis (MS) as a T cell mediated autoimmune disease of the central nervous system (CNS) has evolved into a concept of an immune-mediated disease where complex bi-directional interactions between T cells, B cells and myeloid cells underlie and shape CNS-directed autoimmunity. B cells are now recognized as major contributors to the pathogenesis of MS, largely due to increased understanding of their biology and the profound anti-inflammatory effects demonstrated by B cell depletion in MS. In this chapter we discuss the fundamental roles B cells play in the pathogenesis of MS and review current and future therapeutic strategies targeting B cells in MS, including B cell depletion with various monoclonal antibodies (mAbs) against the B cell surface markers CD20 and CD19, anti-B cell cytokine therapies, blocking Bruton's tyrosine kinase (BTK) in B cells, and various immunomodulatory and immunosuppressive effects exerted on B cells by virtually all other approved therapies for MS.

Original languageEnglish
Title of host publicationTherapies for Retinal Degeneration
Subtitle of host publicationTargeting Common Processes
EditorsAna Martinez
PublisherRoyal Society of Chemistry
Pages134-169
Number of pages36
Edition70
ISBN (Electronic)9781782621454, 9781782629498, 9781788010832, 9781788012096, 9781788013949, 9781788014502
DOIs
StatePublished - 1 Jan 2019

Publication series

NameRSC Drug Discovery Series
Number70
Volume2019-January
ISSN (Print)2041-3203
ISSN (Electronic)2041-3211

Fingerprint

Dive into the research topics of 'CHAPTER 7: B Cell-based Therapies for Multiple Sclerosis'. Together they form a unique fingerprint.

Cite this